TLR7 and cancer: For example, we have shown that RcR and RcD NANPs function as TLR7 agonists and such agents, including the FDA approved TLR7/8 agonist imiquimod, are being explored for use as antivirals, cancer therapeutics and vaccine adjuvants (56–58) (59,60).